A novel t (5; 17) (q35; q21) associated with t (8; 21) (q22; q22) in a patient with acute myeloid leukemia: case report and review of literature
Abstract | PDF | Full Text | How to Cite | Press Release
https://doi.org/10.18632/genesandcancer.232
Kmira Zahra1, Wided Cherif1, Gereisha Ahmed2, Haifa Regaieg1, Ben Sayed Nesrine1, Monia Zaier1, Wided Mootamri2, Yosra Ben Youssef1, Nejia Brahem2, Halima Sennana3 and Abderrahim Khelif1
1 Department of Clinical Hematology, Farhat Hached University Hospital-Sousse-Tunisia, Sousse 4081, Tunisia
2 Department of Cytology, Farhat Hached University Hospital-Sousse-Tunisia, Sousse 4081, Tunisia
3 Department of Cytogenetics, Farhat Hached University Hospital-Sousse-Tunisia, Sousse 4081, Tunisia
Correspondence:
Kmira Zahra, email:[email protected]
Keywords: acute myeloid leukemia; T (8; 21) (q22; q22); T (5; 17) (q35; q21); NPM1/RARA; allogenic stem cells transplantation
Received: April 01, 2023 Accepted: June 14, 2023 Published: June 28, 2023
Abstract
The t (8; 21) (q22; q22) with the resulting RUNX1- RUNX1T1 rearrangement is one of the most common cytogenetic abnormalities in acute myeloid leukemia (AML). It is associated with favorable prognosis. The t (5; 17) (q35; q21) is an uncommon translocation, fuses the gene for the nucleophosmin (NPM) to the retinoic acid receptor α(RARA) and was described essentially in acute promyelocytic leukemia (APL) variant. We present the case of a 19-year-old male patient who developed an AML with t (8; 21) (q22; q22) associated to t (5; 17) (q35; 21). Morphology and immunophenotype of the leukemic cells were compatible with AML. The patient received chemotherapy based on cytarabine and anthracycline without all-trans retinoic acid (ATRA) followed by allogenic stem cell transplantation in first remission. To the best of our knowledge, this is the first report of an association between a rare translocation t (5; 17) and t (8; 21) in AML. In this report, we will discuss the prognosis of this association as well as the treatment.
